• Gonzalo Martínez, Alberto Fuensalida, Pablo Sepúlveda, Juan Francisco Bulnes, Jorge Quitral, Francisco Pacheco, Edith Valenzuela, Rosa Lazen, Alejandra Flores, Ricardo Zalaquett, and Alejandro Martínez.
• División de Enfermedades Cardiovasculares, Pontificia Universidad Católica de Chile, Santiago, Chile.
• Rev Med Chil. 2022 Nov 1; 150 (11): 142214301422-1430.

BackgroundTranscatheter aortic-valve implantation (TAVI) was introduced in 2002 and the first implants in our country were performed in 2010.AimTo review the TAVI experience in our hospital, considering the technology improvements and gained experience throughout this period.Material And MethodsAll patients undergoing TAVI in our center were included. Results and complications were adjudicated according to the Valve Academic Research Consortium-2 (VARC-2) criteria. Patients were divided in 3 groups, according to procedural year: Period 1: 2010-2015 (n = 35); Period 2: 2016-2018 (n = 35); Period 3: 2019-2021 (n = 41). Mortality up to one year after the procedure was recorded.ResultsBetween 2010 and 2021, 111 TAVI procedures were performed. The mean age of patients was 82 years and 47% were women. Risk scores for in-hospital mortality were STS 6.7%, EUROSCORE II 8.0% and ACC/STS TAVR Score 4.9%. The trans-femoral route was used in 88% and a balloon-expandable valve was chosen in 82% of patients. A successful implant was achieved in 96%, with an in-hospital mortality of 1.8%. Mortality at 30 days and 1-year were 2.7 and 9.0%, respectively. During period 3, 100% of implants were successful, with no in-hospital mortality, less vascular complications (p < 0.01), less stroke (p = 0.04), less severe paravalvular leak (p = 0.01) and significantly lower rate of acute complications (p < 0.01).ConclusionsTAVI achieves excellent results. With greater experience and better available technologies, these results are even more favorable.

14 keywords...

hide…